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Abstract
Background: Methotrexate is a chemotherapeutic agent used to treat a variety of cancers. However, the occurrence of
resistance limits its effectiveness. Cytochrome c in its reduced state is less capable of triggering the apoptotic cascade. Thus,
we set up to study the relationship among redox state of cytochrome c, apoptosis and the development of resistance to
methotrexate in MCF7 human breast cancer cells.
Results: Cell incubation with cytochrome c-reducing agents, such as tetramethylphenylenediamine, ascorbate or reduced
glutathione, decreased the mortality and apoptosis triggered by methotrexate. Conversely, depletion of glutathione
increased the apoptotic action of methotrexate, showing an involvement of cytochrome c redox state in methotrexate-
induced apoptosis. Methotrexate-resistant MCF7 cells showed increased levels of endogenous reduced glutathione and a
higher capability to reduce exogenous cytochrome c. Using functional genomics we detected the overexpression of GSTM1
and GSTM4 in methotrexate-resistant MCF7 breast cancer cells, and determined that methotrexate was susceptible of
glutathionylation by GSTs. The inhibition of these GSTM isoforms caused an increase in methotrexate cytotoxicity in
sensitive and resistant cells.
Conclusions: We conclude that overexpression of specific GSTMs, GSTM1 and GSTM4, together with increased endogenous
reduced glutathione levels help to maintain a more reduced state of cytochrome c which, in turn, would decrease
apoptosis, thus contributing to methotrexate resistance in human MCF7 breast cancer cells.
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Introduction
Methotrexate (MTX) is a chemotherapeutic agent widely used,
alone or in combination with other chemotherapeutic agents, for
the treatment of a range of cancers, such as breast cancer,
osteosarcoma, head and neck cancer, lymphoma and acute
lymphoblastic leukemia [1]. As a structural analogue of folic acid,
MTX is a high affinity inhibitor of dihydrofolate reductase
(DHFR) by competing with dihydrofolate for the active site.
DHFR catalyzes the NADPH-dependent reduction of dihydrofo-
late to tetrahydrofolate involved in the biosynthesis of thymidylate,
hypoxantine and glycine, needed for DNA synthesis [2–4]. Once
DHFR is inhibited by MTX, there is suppression of DNA
synthesis and cell proliferation is affected. However, the main
drawback of using MTX in cancer therapy is the occurrence of
resistance upon treatment, thus compromising its effectiveness.
Several MTX resistance mechanisms had been described such as
gene amplification of the dhfr locus [5,6], deficiency in MTX
transport [7,8] or MTX polyglutamation [9], expression of the
MDR phenotype and mutations of the target (DHFR protein)
[10]. Altered gene or miRNA expression also contribute to MTX
resistance such as increases in AKR1C1 [11], S100A4 [12],
caveolin-1, enolase-2, PRKCA [13], DKK1, EEF1A1, and
UGT1A family [14,15], and the decrease of E-Cadherin [13] or
miR-224 [16].
Reduced glutathione (GSH) and Glutathione S-transferases
(GSTs) have been implicated in the development of drug
resistance in cancer chemotherapy [17,18]. The GSTs enzymatic
family belongs to a Phase II detoxification program functioning as
a cellular protection from attack by reactive electrophiles
associated to environmental stresses and drugs [19]. This family
is mainly responsible for the conjugation of GSH to electrophilic
compounds and includes three main types, cytosolic, mitochon-
drial and membrane-bound microsomal. Cytosolic GSTs are
divided into seven classes: alpha (A), Mu (M), Omega (O), Pi (P),
Sigma (S), Theta (T) and Zeta (Z) [20–23]. GSTs are thought to be
involved in the development of drug resistance via direct
detoxification or by regulation of the MAP kinase pathway,
specifically JNK-pathway as reviewed in [19].
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Cytochrome c (cyt c) is a heme-protein bound to the
mitochondrial inner membrane by an interaction with the anionic
phospholipid cardiolipin, which keeps cytochrome c in its proper
location and prevents its release to the cytosol [24]. Under
physiological conditions, cytochrome c is responsible for the
electron transfer between complexes III and IV of the mitochon-
drial electron transport chain whereas under oxidative stress, the
peroxidase activity of cytochrome c is activated, cardiolipin
becomes peroxidized, and loses its affinity for cytochrome c
allowing its release to the cytosol [25,26]. Once in the cytosol,
cytochrome c can only induce apoptosis in its oxidized form [27–
31]. The presence of high levels of cytosolic GSH holds the
released cytochrome c inactive in a reduced state, thus preventing
the progression of the apoptotic cascade [32,33].
In this study, we investigated the effect of the reduction state of
cytochrome c on MTX sensitivity and apoptosis and its
relationship with the different GSTs overexpressed in MCF7
breast cancer cells resistant to MTX, to evaluate a possible
connection between GSTs and GSH in the reduction state of
cytochrome c and the development of MTX resistance.
Materials and Methods
Cell lines and cell culture
The following human cell lines were used: MCF7, MDA-MB-
468 and 1026 M MTX-resistant MCF7 cells from breast cancer;
SaOs-2 and 1026 M MTX-resistant SaOs-2 cells from osteosar-
coma; and HT-29 and CaCo-2 cells from colon cancer. Resistant
cells were obtained previously in the laboratory upon incubation
with stepwise concentrations of MTX (Almirall, Barcelona, Spain)
as described in [11]. In all experimental procedures, cells were
grown in Ham’s F12 medium lacking the final products of DHFR
activity, glycine, hypoxanthine and thymidine (-GHT), and
supplemented with 7% v/v dialyzed fetal bovine serum (GIBCO,
Life Technologies, Madrid, Spain), 14 mM sodium bicarbonate
(1.176 g/l), penicillin G (100 U/ml) and streptomycin (100 mg/l).
Cells were maintained at 37uC in a humidified atmosphere of 5%
CO2 in air. Before reaching 70% confluence, cells were sub-
cultured by treatment with 0.05% trypsin in PBS 16. All these
components were purchased from Sigma-Aldrich (Madrid, Spain).
Oxygen consumption assay
Cellular oxygen consumption was monitored polarographically
with a Clark-type oxygen electrode using Hansatech Oxygraph
Measurement System (Hansatech, Norfolk, UK). The assay was
performed using 66104 cells/ml in the presence or in the absence
of 5 mM TMPD or 300 mM ASC in 1 ml of PBS (pH 7.4) as
experimental medium at 37uC. Oxygen consumption was
measured during 5 min for each condition and determined by
the slope calculated directly by the Oxygraph Plus Software.
Cell viability assay
Cell viability was assessed by the MTT (3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide) assay [34] in 6-well dishes.
Cells were incubated with 500 mg of MTT and 0.270 mg of
sodium succinate (Sigma-Aldrich, Madrid, Spain) and allowed to
react for 2 h at 37uC. The medium was removed and 1 ml of the
solubilization reagent (0,57% acetic acid and 10% SDS in DMSO
(dimethyl sulfoxide)) was added (Applichem, Ecogen, Barcelona,
Spain). Cell viability was measured at 570 nm in a WPA S2100
Diode Array Spectrophotometer. The results were expressed as
percentage of cell survival relative to the control (untreated cells).
Microarrays
Gene expression was analyzed by hybridization to GeneChipH
Human Genome U133 PLUS 2.0 microarrays from Affymetrix,
containing 54,675 transcripts and variants. Total RNA for cDNA
arrays was prepared from triplicate samples from both control and
resistant cells using the RNAeasy Mini kit (Qiagen, Madrid, Spain)
following the recommendations of the manufacturer. The integrity
of the RNA species was checked using the Bioanalyzer 2100
system (Agilent, Madrid, Spain). Labeling, hybridization and
detection were carried out following the manufacturer’s specifica-
tions.
Microarrays data analyses
Quantification was carried out with GeneSpring GX 12.0
software (Agilent, Madrid, Spain), which allows multi-filter
comparisons using data from different experiments to perform
the normalization, generation of lists and the functional classifi-
cation of the differentially expressed genes. The input data was
subjected to preprocess baseline transformation using the RMA
summarization algorithm using the median of control samples.
After grouping the triplicates of each experimental condition, lists
of differentially expressed genes could be generated by using
volcano plot analysis. T-test unpaired was applied using asymp-
totic p-value computation and multiple testing correction of
Benjamini-Hochberg false discovery rate, FDR. The expression of
each gene was reported as the ratio of the value obtained for the
resistant condition relative to the control condition after normal-
ization and statistical analysis of the data. The corrected p-value
cut-off applied was of ,0.05; then the output of this statistical
analysis was filtered by fold expression, selecting specifically those
genes that had a differential expression of at least 2-fold.
RT-Real-Time PCR
Total RNA was extracted using the UltraspecTM RNA reagent
(Biotecx, Ecogen, Barcelona, Spain) following the manufacturer’s
instructions. Complementary DNA (cDNA) was synthetized in a
total volume of 20 ml by mixing 1 mg of total RNA, 125 ng of
random hexamers (Roche, Mannheim, Germany), in the presence
of 75 mM KCl, 3 mM MgCl2, 50 mM Tris-HCl buffer, pH 8.3,
10 mM dithiothreitol (Invitrogen, Life Technologies, Madrid,
Spain), 20 units of RNAsin (Promega, Madrid, Spain), 0.5 mM
dNTPs (Applichem, Ecogen, Barcelona, Spain) and 200 units of
MLV-reverse transcriptase (Invitrogen, Life Technologies, Ma-
drid, Spain). The reaction mix was incubated at 37uC for 1 h and
the cDNA product was used for subsequent amplification.
Gene expression levels were quantified by SYBR Green RT-
Real Time PCR reaction in a final volume of 20 ml with specific
forward and reverse primers, using the StepOnePlusTM detection
system (Applied Biosystems, Life Technologies, Madrid, Spain).
The sequences of the forward and reverse primers (Sigma-Aldrich,
Madrid, Spain) are given in Table 1.
Table 1. Primer sequences.




The sequences for the forward and reverse primer for detection of GSTM1,
GSTM4 and HPRT mRNA levels used for RT-Real Time PCR are given.
doi:10.1371/journal.pone.0063276.t001
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Changes in gene expression were calculated using the quanti-
tative DDCt method and normalized against Hypoxanthine-
phosphoribosyl transferase (HPRT) in each sample.
GSTM1 and GSTM4 protein levels
MCF7 cells, either sensitive or MTX-resistant, were harvested
from confluent dishes and total extracts were prepared according
to [14]. Total extracts (80 mg) were resolved on a 15% SDS-PAGE
(AppliChem, Ecogen, Barcelona, Spain) and transferred to PVDF
membranes (Immobilon P, Millipore, Madrid, Spain) using a
semidry electroblotter. The membranes were probed with anti-
GSTm antibody (FL-218, sc-292368) (Santa Cruz Biotechnology
Inc, Heidelberg, Germany) 1:200 dilution, OVN at 4uC. Signals
were detected using ImageQuant LAS 4000 Mini Technology
(Amersham, GE Healthcare Life Sciences, Barcelona, Spain) with
rabbit secondary horseradish peroxidase–conjugated antibody
(P0399) (Dako, Barcelona, Spain) 1:5000 dilution, for 1 h at room
temperature. To normalize the results blots were reprobed with an
antibody against tubulin (Cp06) (Calbiochem, Millipore, Merck,
Madrid, Spain) 1:400 dilution, OVN at 4uC and detected with
anti-mouse (NIF 824) (Amersham, GE Healthcare Life Sciences,
Barcelona, Spain) 1:2500 dilution, for 1 h at room temperature.
Inhibition of GSTM1 and GSTM4 expression levels
GST expression was inhibited by specific PPRH-hairpins (hp), a
new class of DNA-hairpin molecules able to silence gene
expression [35,36]. The Triplex-Forming Oligonucleotide Target
Sequence Search software (M.D. Anderson Cancer Center,
Houston, TX) (spi.mdanderson.org/tfo/) was used to design the
hairpins. BLAST analyses were performed to check for the
specificity of each sequence. Cells were plated in 6-well dishes in
1 ml of medium the night before transfection and each hairpin was
mixed with N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammo-
nium methylsulfate (DOTAP) (Roche, Mannheim, Germany) at
the appropriate oligonucleotide–DOTAP molar ratio (1:100) for
15 min at RT before lipofecting the cells. The sequences of the
hairpins (Sigma-Aldrich, Madrid, Spain) are listed in Table 2.
For RNA determination, cells were transfected and total RNA
was extracted 30 h later. Gene expression was quantified as
described above.
For viability assays, cells were incubated with each hairpin for
24 h before MTX treatment. Survival was determined after 3 days
in sensitive MCF7 cells or 6 days in resistant MCF7 and SaOs-2
cells.
Apoptosis
Apoptosis was determined by the Rhodamine 123/Propidium
Iodide (PI) assay. Cells (66104) were plated in 6-well dishes, and
treated with the different agents (TMPD, ascorbate, veratridine)
alone or in combination with MTX for the indicated times and
concentrations. Then cells were incubated for 30 min with 5 ml of
Rhodamine 123 (1 mg/ml). All the cells in each well were harvested
and centrifuged at 8006 g for 5 min. The cell pellet was washed
twice with 1 ml of PBS 16+1%BSA solution and resuspended in
500 ml of PBS 16+BSA 1% solution containing 0.5 ml PI (5 mg/
ml). The entire procedure was performed at 4uC. All these reagents
were purchased from Sigma-Aldrich (Madrid, Spain). Samples
were analyzed by flow cytometry in the Coulter Epics XLTM
cytometer (Beckman, Barcelona, Spain) at an excitation wave-
length of 488 nm by reading the fluorescence of rhodamine123 at
525 nm. Cells that were negative for both rhodamine123 and PI
were counted as the apoptotic population. Summit v4.3 software
was used to analyze the data.
GSH endogenous levels
Endogenous GSH levels were determined using the Glutathione
Assay Kit, Fluorimetric (Sigma-AldrichH) based on a fluorimetric
reaction catalyzed by GSTs between monochlorobimane (MCB), a
thiol probe, and GSH. Briefly, the assay was performed with
66104 sensitive and resistant MCF7 cells and the formation of the
fluorescent adduct GSH-monochlorobimane was monitored at
390 nm for excitation and 478 nm for emission during 1 h.
Exogenous cyt c reduction by cytoplasmic cell extracts
Cytoplasmic cell extracts were obtained from MCF7 cells. Cells
were collected in ice-cold PBS by scraping and centrifuged at
1,5006 g for 10 min. The cell pellet was resuspended in 3 ml of
lysing buffer prepared according to Borutaite&Brown [29] and
homogenized in Glass/Teflon Potter Elvehjem homogenizer (20
strokes). The homogenate was further centrifuged in the same
conditions as above and the supernatant was further centrifuged at
22,0006g for 30 min and the resulting supernatant corresponds to
the cytoplasmic extract. The entire procedure was performed at
4uC. The reduction of exogenous cytochrome c by cytoplasmic
extracts (100 mg/ml of total protein) was followed spectrophoto-
metrically. The analysis measured the absorbance spectra between
500 and 600 nm wavelengths after incubation for 15 min at 37uC
of exogenous cytochrome c (10 mM) with cytoplasmic cell extracts
from sensitive or resistant MCF7 cells. Reduction level of
cytochrome c was expressed as absorbance at 550 nm minus
absorbance at 535 nm and was normalized to the protein of
cytosolic extract used.
In vitro Glutathionylation
The glutathionylation of MTX catalyzed by GSTs was
determined in vitro and in cell free extracts. In vitro, the reaction
was performed by incubating MCB (100 mM), GSH (30 mM) and
GST (0.25 U) in the absence or the presence of different
concentrations of MTX in 0.1 M potassium phosphate buffer
pH 7.0 [37]. The reaction was performed at 37uC for 15 min and






The sequences for the polypurine reverse Hoogsteen hairpins used for specific inhibition of GSTM1, GSTM4 or GSTA4 as well as the scrambled negative control are
given.
doi:10.1371/journal.pone.0063276.t002
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Figure 1. O2 consumption analysis upon treatment with TMPD or ascorbate (ASC). A) Representative image of changes in O2
concentration over time in cell extracts under basal conditions and after treatment with TMPD or ASC. The basal consumption rate in MCF7 cells (B–C)
was 0.0335 nmol O2/ml/min and 0.047 nmol O2/ml/min in SaOs-2 cells (D–E). The results are expressed as the ratio of O2 consumption rate in each
condition relative to basal consumption levels and represent the mean value 6 SE of three independent experiments. * p,0.05.
doi:10.1371/journal.pone.0063276.g001
Figure 2. Effect of TMPD or ascorbate (ASC) in combination with MTX on cell viability. Cells (66104) were incubated in 1 ml of medium
with TMPD (A) or ASC (B) either alone or in combination with MTX at the indicated concentrations, for 3 or 6 days, respectively, and cell viability was
determined using the MTT assay. TMPD or ASC were added to the cells 6 h before MTX. Results are expressed as the percentage of surviving cells
compared to the control (untreated cells) and represent the mean 6 SE of 3 experiments. * p,0.05.
doi:10.1371/journal.pone.0063276.g002
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the fluorescence corresponding to the MCB-GSH adduct was
measured as described above.
In cell free extracts, the reaction was performed as follows.
Parental or MCF7 MTX-resistant cells (46105) were harvested
and washed twice with ice-cold PBS 16. The pelleted cells were
then resuspended in 100 ml of PBS 16-1% Triton X-100, kept on
ice for 15 minutes and centrifuged at 15,0006 g for 15 minutes
(4uC). The corresponding supernatant was collected (300 mg) and
used for the glutathionylation reaction in the absence or in the
presence of MTX for 15 min at 37uC.
MCB, reduced glutathione and GST were purchased from
Sigma-Aldrich (Madrid, Spain). MCB and GSH were resuspended
in DMSO and GST was resuspended at a concentration 0.25 U/
ml in 0.01 M potassium phosphate pH 7.0 and 30% glycerol
buffer.
Statistical analysis
Data are presented as the mean 6 SE for at least three different
experiments. Analyses were performed using SPSS v.18.3
software. Differences with p-value,0.05 were considered signifi-
cant.
Results and Discussion
Effect of TMPD and ascorbate on the cytotoxicity
produced by methotrexate
Tetramethylphenylenediamine (TMPD) and ascorbate (ASC)
have been described as external reductants of cytochrome c both
in cytosol and mitochondria [29,38,39]. In this direction, we used
both agents to study the role of the reduced state of cytochrome c
in the sensitivity to methotrexate.
Figure 3. Effect of TMPD and ascorbate (ASC) on apoptosis induced by MTX. Cells were incubated with TMPD (A) or ASC (B) either alone or
in combination with MTX at the indicated concentrations for 18 h. TMPD or ascorbate were added 12 h before MTX. Changes in mitochondrial
membrane potential were determined using the Rhodamine 123/Propidium Iodide assay. Apoptosis is expressed in fold change compared to
untreated cells. Results represent the mean6 SE of 3 different experiments. Staurosporine (STP) was used as a positive control. **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0063276.g003
Figure 4. Effect of GSH on the cytotoxicity caused by MTX.
MCF7 sensitive cells (66104) were plated in 1 ml medium and treated
with 1 mM GSH (light grey bars) for 2 h before incubation with MTX.
Survival was assessed by the MTT assay 4 days later. Results are
expressed as the percentage of survival compared to non-treated cells
and represent the mean 6 SE of at least 3 experiments. **p,0.01,
***p,0.001.
doi:10.1371/journal.pone.0063276.g004
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Figure 5. Effect of veratridine (VERA) and GSH on MTX induced apoptosis. Cells were incubated with veratridine alone or in combination
either with MTX or MTX plus GSH, at the indicated concentrations. Veratridine was added 6 h before MTX. Incubation with exogenous GSH started
8 h before the addition of MTX. In the triple combination, cells were incubated 2 h with GSH, then veratridine was added and 6 h later, treatment
with MTX was performed. Apoptosis was assessed 18 h after MTX addition by changes in mitochondrial membrane potential as determined by the
Rhodamine 123/Propidium Iodide assay and it is expressed in fold change compared to untreated cells. Results represent the mean 6 SE of 3
different experiments. Staurosporine (STP) was used as a positive control. * p,0.05.
doi:10.1371/journal.pone.0063276.g005
Figure 6. Endogenous GSH levels and cytochrome c redox capacity in cytosolic extracts. A) GSH endogenous levels were determined as
described in Methods using cytoplasmic extracts from sensitive and MTX-resistant MCF7 cells (66104). GSH content was calculated in nmols of GSH/
mg of total protein (mean 6 SE). Results are expressed as the ratio between resistant and sensitive cells. B) Cytoplasmic extracts from sensitive and
resistant cells were incubated for 15 min with exogenous cytochrome c (10 mM). A sample with DTT and no cell extract was considered as the
maximum value for cytochrome c reduction. The reduction level of cytochrome c was calculated as the difference between the absorbance at
550 nm and at 535 nm. The results are expressed as the percentage of reduction observed in the resistant extracts compared to the sensitive cells
and represent the mean 6 SE of at least three experiments. * p,0.05.
doi:10.1371/journal.pone.0063276.g006
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First, the reduction of cytochrome c by TMPD or ASC
treatment in MCF7 cells was confirmed by determining the
changes in O2 consumption using an oxygraph upon treatment
with these chemical reagents. One of the classic end-points to
analyze mitochondrial function is to assess the changes in oxygen
consumption since O2 is the ultimate electron acceptor [40]. This
method is commonly used [39,41–44], it calculates the variation of
O2 concentration over time and offers the unique advantage of
being able to add other components during the experiment. The
slope of the graph represents the O2 consumption rate. As shown
in figure 1, TMPD and ASC addition increased O2 consumption
in MCF7 cells by 18.5 and 3.9 fold, respectively (Figure 1, B and
C). In addition, the oxygen consumption rate was also determined
in SaOs-2 cells upon addition of the 2 reducing agents, TMPD
and ASC, causing an increase of 8.6 and 7.7 fold, respectively
(Figure 1, D and E).
MCF7 cells were incubated with 5 mM TMPD or 300 mM
ascorbate, either alone or in combination with 30 nM MTX and
cell viability was determined after 3 or 6 days, respectively. The
incubation with TMPD and ascorbate started 6 h before the
addition of MTX. The presence of TMPD or ascorbate, which
alone did not cause significant cell death, decreased the cytotoxic
effect of MTX (Figure 2A, B). The reduction in cytotoxicity was
more evident in the presence of TMPD with a recover in cell
survival of 26%. The combination of MTX with ascorbate was less
effective as the presence of ascorbate only counteracted the action
of MTX by 14%.
To assess whether this effect was cell type specific, different cell
lines were incubated with 5 mM TMPD and then treated with
MTX. The presence of TMPD also decreased the cytotoxic effect
of MTX by 15.1% in MDA-MB-468 cells, by 17.5% in SaOs-2
cells, by 10.5% in HT-29 cells, and by 21% in CaCo-2 cells.
Since the cytotoxic effect of MTX decreased in the presence of
TMPD or ASC, we could hypothesize that the redox state of
cytochrome c might be involved in the sensitization of cells to
MTX-induced apoptosis in different cell lines.
TMPD and ascorbate decrease the apoptotic effect of
MTX
It has been demonstrated that MTX can induce apoptosis
mediated by cytochrome c release [45,46]. For this reason, we
wanted to get further insight into the role of cytochrome c redox
state in MTX-induced apoptosis. Levels of apoptosis were
determined by the loss of mitochondrial membrane potential
(MMP) using the Rhodamine 123/Propidium Iodide assay.
Incubation of MCF7 cells with 50 nM or 100 nM MTX revealed
an increase in apoptosis of 1.65-fold and 1.9-fold, respectively,
referred to untreated cells. Treatment with TMPD (figure 3A) or
ascorbate (figure 3B) before MTX prevented this apoptotic effect
by 37% and 20%, respectively. Thus, by reducing cytochrome c
with either TMPD or ascorbate, we were able to decrease MTX-
induced apoptosis. The preventing effect on apoptosis caused by
TMPD was also demonstrated in the breast cancer cell line MDA-
MB-468 as well as in HT-29 colon cancer cells.
Since TMPD was shown to be freely permeable across
cytoplasmic and mitochondrial membranes [38] the reduction of
cytochrome c could take place in the mitochondria or after its
release, as shown by Borutaite and Brown [29]. Regardless the
exact mechanism, it is clear from our results that the reduced state
of cytochrome c correlates with a lower proapoptotic effect of
MTX.
Effect of addition or depletion of GSH on MTX action
The redox state of cytochrome c is partially responsible for its
apoptotic activity. Our results showed that exogenous reducing
agents of cytochrome c were able to modulate the response
towards MTX (figures 2 and 3). It has been described that GSH
can reduce cytochrome c [27,31,47], and therefore we wanted to
study whether GSH could exert a role in MTX resistance in
MCF7 cells.
GSH is one of the most important regulators of intracellular
redox balance, performing an antioxidant cell protective action,
cycling between its reduced (GSH) and oxidized forms (GSSG)
[48]. Reactive oxygen species (ROS) mediated apoptotic signaling
is associated with a decrease of cellular GSH levels and loss of
cellular redox balance [49] and high levels of GSH have been
associated to drug resistance [50–52].
As shown in Figure 4, incubation with exogenous GSH
decreased the cytotoxicity induced by MTX. These results suggest
that a more reduced state of cytochrome c correlates with less
MTX cytotoxicity, as previously observed with TMPD or ASC.
To explore the role of GSH on MTX-dependent apoptosis we
used veratridine to decrease GSH levels [53]. As shown in Figure 5,
the apoptotic effect provoked by the combination of veratridine
plus MTX was higher than the summation of both agents by
themselves. Interestingly, the addition of 1 mM GSH decreased
MTX-induced apoptosis and counteracted the increase in
apoptosis caused by veratridine.
These results indicate a possible role of GSH in MTX-induced
apoptosis. It has been suggested that endogenous GSH contributes
to maintain cytochrome c in its reduced state under physiological
conditions and prevents its apoptotic effect [27,32,33,43]. A lower
reduced environment caused by GSH depletion would favor
cytochrome c induced apoptosis upon MTX incubation.
GSH endogenous levels were determined in cell extracts from
sensitive and resistant cells. As shown in figure 6A, GSH content
was 6.2 times higher in resistant cells, indicating that the
detoxifying capacity of the cytoplasm in resistant cells was higher
than in sensitive cells. To analyze this, exogenous cytochrome c
was incubated with either sensitive or resistant cytoplasmic cell
extracts. Changes in cytochrome c redox state were measured
spectrophotometrically as described. The results in Figure 6B
Table 3. Differentially expressed GSTs in MCF7 MTX-resistant cells.
Gene Symbol Raw resistant Raw sensitive Fold Change Corrected p-value
GSTM1 129 58 2.2 0.01288
GSTM2 182 76 2.4 0.02732
GSTM4 151 67 4.8 0.02732
Microarray data analyses were performed with GeneSpring GX 12.0 software as described. For each GSTM isoform, it is expressed the mean of the raw value in sensitive
and resistant cells, the fold change in expression after normalization of the data, as well as the corrected p-value after Benjamini-Hochberg FDR filtering.
doi:10.1371/journal.pone.0063276.t003
Cytochrome C Redox State and Resistance to MTX
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confirmed that resistant cells had a higher capacity to reduce
exogenous cytochrome c (60%). These results support the idea that
the higher reduced environment present in MTX-resistant cells
would contribute to overcome the apoptotic stimuli, in this case
produced by MTX, and favor the resistant phenotype.
Endogenous levels of GST in sensitive and MTX-resistant
MCF7 cells
Treatment with exogenous GSH prior to MTX had the same
effect on cell viability that preincubation with TMPD or ascorbate,
both known cytochrome c reducing agents. Therefore, an increase
in GSH would keep cytochrome c reduced and could help the cells
to reduce the apoptotic effect induced by MTX. To explore more
in detail this possibility and its mechanism in our model of MTX
resistance, we searched for genes related with GSH and the
balancing redox environment of the cell.
Whole genome expression microarrays of sensitive and MTX-
resistant MCF7 cells had been previously performed in the
laboratory [14] and deposited in the Gene Expression Omnibus
(GEO) database with series accession number GSE16648.
Interestingly, analyses of the data demonstrated that different
isoforms of the GST family, namely GSTM1, GSTM2 and
GSTM4, were overexpressed in MCF7 resistant cells compared to
their sensitive counterparts (Table 3).
Several examples in the literature have established a link
between GSTM1 and GSTM4 overexpression with drug resis-
tance [54–58], for this reason GSTM1 and GSTM4 were selected
for further study. On the other hand, GSTM2 is a muscle-specific
human GSTm isoform specially enriched in in the cytoplasm of
skeletal and cardiac muscle [59]. Increased or decreased
expression of GSTM2 has been related to cancer predisposition
or promotion, such as lung cancer [60] or ovarian teratoma [61].
However, no clear evidence between GSTM2 increased levels and
drug resistance has been reported, and therefore this isoform was
not further studied.
The endogenous levels of GSTM1 and GSTM4 were validated
in sensitive and MTX-resistant MCF7 cells at mRNA and protein
level. As it can be observed in Figure 7 both GSTM1 (A) and
GSTM4 (B) mRNA levels were increased 2.2 and 2.77-fold,
respectively, in MCF7 resistant cells, confirming GSTs overex-
pression detected in the microarray experiments. This effect was
translated at the protein level. MTX-resistant MCF7 cells showed
Figure 7. Validation of GSTM1 and GSTM4 overexpression in MCF7 MTX-resistant cells. GSTM1 (A) and GSTM4 (B) mRNA expression
levels were determined by RT-Real Time PCR in sensitive and 1026 M MTX-resistant MCF7 cells. Results are expressed as the fold changes in
expression compared to sensitive cells and are the mean6 SE of at least 3 different experiments. C) GSTm protein levels were determined by Western
blot in sensitive (S) and resistant (R) cells and quantified using the ImageQuant software (GE Healthcare, Barcelona, Spain). Blots were normalized
against tubulin levels. Values represent the mean 6 SE of three different experiments and are expressed as fold increase in GSTm protein levels
relative to the control. **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0063276.g007
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Figure 8. Effect of GSTM1 and GSTM4 inhibition on their mRNA levels and on sensitivity towards MTX. Effect on mRNA levels: MCF7
cells (66104) were plated in 1 ml of medium and transfected 18 h later with specific hairpins against GSTM1 (hpGSTM1) (A) or GSTM4 (hpGSTM4) (B).
mRNA levels were determined 30 h after transfection. Results are expressed as changes in expression compared to the control non-transfected cells
and are the mean 6 SE of at least 3 different experiments. A scrambled hairpin was used as a negative control (hpSC). Effect on MTX cytotoxicity:
MCF7 cells (66104) were plated in 1 ml of medium and transfected 18 h later with either hpGSTM1 (C) or hpGSTM4 (D). MTX was added 24 h after
transfection and viability assayed by MTT 3 days later. Results are expressed as the percentage of cell survival compared to the control non-
transfected cells and are the mean 6 SE of at least 3 different experiments. *p,0.05, **p,0.01. E) In vitro MTX glutathionylation reaction. It was
determined by calculating the differences between the fluorescence of the MCB-GSH adduct in the control reaction minus that in the presence of
MTX. GST activity is expressed as nmols of GSH transferred by GST per minute. F) MTX glutathionylation reaction in cell free extracts. The formation of
MCB-GSH adduct was followed by its fluorescence using cell free extracts from sensitive or resistant MCF7 cells in the absence or in the presence of
MTX. Results are expressed as relative fluorescence units (RFU) per mg of total protein.
doi:10.1371/journal.pone.0063276.g008
Cytochrome C Redox State and Resistance to MTX
PLOS ONE | www.plosone.org 9 May 2013 | Volume 8 | Issue 5 | e63276
2.8 times more GSTm levels that sensitive cells as determined in
Western blot assays (C & D).
Overexpression of different isoforms of GSTs was also detected
in other MTX-resistant cell lines such as SaOs-2, HT-29 and
CaCo-2 but not in MDA-MB-468 cells (GSE16648-GEO).
Inhibition of GSTM1 and GSTM4 increases the
cytotoxicity produced by MTX
To establish a role of GSTs in the sensitivity to MTX, we
silenced GSTM1 and GSTM4 using specific template polypurine
hairpins, a new class of molecules for specific and effective gene
silencing developed in the laboratory [35,36].
As it can be observed in Figure 8C & D, MTX cytotoxicity in
MCF7 cells increased when either GSTM1 or GSTM4 were
inhibited by specific PPRH-hairpins (Figure 8A & B), demonstrat-
ing the role of these specific GSTs in diminishing the cytotoxicity
produced by MTX. Interestingly, GSTM1 and GSTM4 inhibition
also increased the sensitivity to MTX in MTX-resistant cells, by
23% in the case of GSTM1 and 17% in the case of GSTM4. In a
previous work performed in our laboratory, MTX-resistant MCF7
cells were found to have the dhfr locus amplified [14]. Therefore, it
is noteworthy that inhibition of GSTM1 and GSTM4 increased
the sensitivity towards MTX even in the presence of multiples
copies of the dhfr gene. In addition, we used SaOs-2 cells as a
model of MTX-resistant cell line with no amplification of the dhfr
locus [14]. For this cell line, a hairpin against GSTA4 was used
since this isoform was overexpressed in this MTX-resistant cell
line. It was observed an increase in the sensitivity to MTX of 35%.
Apoptosis was also determined after incubating hairpins against
GSTM1 and GSTM4 in MCF7 cells resistant to MTX. Apoptosis
was increased 2.5 or 2 fold after knocking down GSTM1 and
GSTM4, respectively.
As a mechanism of resistance in MTX-resistant cells, we wanted
to assess whether MTX was susceptible of glutathionylation by
GSTs given their role in the detoxification of exogenous
compounds and drug resistance. As can be observed in Figure 8E
& F, GSH can be transferred to MTX by GST activity.
Others studies relate levels of GSH with resistance to anti-tumor
agents such as doxorubicin [50] and there are several examples in
the literature that link increased GSH levels with breast cancer
patients [62] or increased GSH levels and poor response to
alkylating agents in MCF7 cells [51].
In addition, overexpression of GSTs in mammalian tumor cells
has been implicated with resistance to various anticancer agents
and chemical carcinogens [20,23].
In addition to their classic catalytic functions in detoxification of
electrophilic compounds, GSTs are also involved in the regulation
of other mechanisms that impact cell survival pathways, such as
the JNK-pathway [19,63]. Interestingly, overexpression of
GSTM1 [64] and GSTP [65] has been described to prevent the
activation of MAPK pathway, thus avoiding the apoptosis cascade.
This link with MAPK-mediated signaling could provide a possible
mechanism of action of GST in drug-resistant cells. In addition,
overexpression of GSTs has been associated with resistance to
many therapeutic drugs [19], even if they are not GSTs substrates
[17,66]. Another observation that argues in favor of GSTs playing
a role in the modulation of apoptosis is the finding that Bee
Venom, an inducing-apoptosis agent, increases the expression of
apoptotic proteins, e.g. Bax, Bid, p53, p27, cytochrome c but
decreases the expression of anti-apoptotic proteins like Bcl-2, Bcl-
xL, and also GSTs [67]. Although there is no evidence of s-
glutathionylation of cytochrome c in vivo, direct interaction
between GSH and cytochrome c has been described in vitro [68].
Therefore, besides MTX glutathionylation, GST might help to
maintain, directly or indirectly, cytochrome c in a reduced state.
According to our results, inhibition of GSTM1 and GSTM4
increases the sensitivity to MTX in sensitive cells, which is in
keeping with the overexpression of these particular isoforms in
breast cancer cells resistant to MTX. These observations suggest a
role of GSTs in MTX drug resistance.
Conclusions
There is a relationship between cytochrome c redox state,
apoptosis and development of MTX-resistance. In the presence of
exogenous reducing agents of cytochrome c such as TMPD,
ascorbate or GSH, MCF7 cells were less prone to apoptosis, which
led to a lower MTX cytotoxicity. On the other hand, depletion of
endogenous GSH using veratridine caused an increase in the
apoptotic action of MTX, which was reverted by the addition of
exogenous GSH. Furthermore, endogenous levels of GSH were
higher in MTX-resistant MCF7 cells. These observations suggest
that cytochrome c redox state modulates MTX sensitivity. This
effect was not restricted to a specific cell type since treatment with
TMPD also decreased MTX cytotoxicity in MDA-MB-468, SaOs-
2, HT-29 and Caco-2 cells.
Inhibition of GSTM1 and GSTM4, which are overexpressed in
MTX-resistant MCF7 cells, caused an increase in MTX
cytotoxicity in sensitive and resistant MCF7 cells. Furthermore,
inhibition of GSTA4 in MTX-resistant Saos-2 cells increased
sensitivity to MTX.
In summary, we conclude that in MCF7 breast cancer cells, the
overexpression of specific GSTs and increased GSH levels
contribute to a more reduced environment. Thus, the presence
of a more reduced cytochrome c would help the cells to avoid
apoptosis and contribute to the resistant phenotype.
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